Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
In order to provide increased confidence in our COVID-19 test results as SARS-CoV-2 continues to mutate, our TaqPath COVID-19 2.0 tests employ an advanced assay design with increased target redundancy to compensate for both currently known and future SARS-CoV-2 mutations.
This design is used across both of our TaqPath COVID-19 2.0 tests.
Internal control | Sample type | Limit of detection | Turnaround time | Approved sample | Approved system | |
---|---|---|---|---|---|---|
TaqPath COVID-19 Fast PCR Combo Kit 2.0Download flyer › | RNase P | Symptomatic individuals: Raw saliva | 750–1,000 GCE/mL* | ~2 hours | Lysis (Applied Biosystems |
|
TaqPath COVID-19 RNase P Combo Kit 2.0Download flyer › | Symptomatic and asymptomatic individuals:
| 75 GCE/mL LOD* | ~3 hours | Thermo Scientific KingFisher Applied Biosystems MagMAX |
*LOD of 750 GCE/mL using QuantStudio 7 Flex instrument (384-well); LOD of 1,000 GCE/mL using QuantStudio 5 instrument (96-well, 0.2 mL)
Thermo Fisher Scientific continues to provide gold standard testing technology with our evolved suite of PCR-based TaqPath COVID-19 2.0 tests, which were developed to help laboratories quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
Features of the TaqPath COVID-19 2.0 test menu:
Find the approved Instructions for Use (IFU) for your country. (Note: Product availability varies by country.)
For In Vitro Diagnostic Use. Regulatory requirements vary by country. Product may not be available in your geographic region. © 2021 Thermo Fisher Scientific Inc.
All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.